Table 2. Univariate and multivariate survival analysis using Cox proportional hazard model for overall survival.

Variables	Univariate	Multivariate
	p value	HR	95% CI	p value
CDH17
[−] vs. [+] vs. [++]	0.030*	0.640	0.425-0.963	0.032*
CLDN18
[−] vs. [+] vs. [++]	0.549	0.810	0.541-1.214	0.308
CLDN7
[−] vs. [+] vs. [++]	0.131	0.870	0.594-1.276	0.476
Age
[≤60] vs. [61-70] vs. [≥71]	0.473	1.015	0.989-1.042	0.252
Sex
[Male] vs. [Female]	0.903	1.268	0.692-2.325	0.443
Tumor size (mm)
[≤50] vs. [51-100] vs. [≥101]	0.091	0.720	0.445-1.164	0.18
Stage
[IIA-B] vs. [IIIA-C] vs. [IV]	<0.001**	2.493	1.284-4.837	0.007*
T classification
[T1b+T2] vs. [T3] vs. [T4a+T4b]	0.0013**	1.787	0.966-3.309	0.064
Lymphatic invasion
[ly0-1] vs. [ly2-3]	0.133	1.381	0.67-2.845	0.381
Venous invasion
[v0-1] vs. [v2-3]	0.717	0.568	0.309-1.046	0.069
# of LN metastases
[5-10] vs. [11-20] vs. [≥21]	<0.001**	1.753	1.143-2.688	0.010*
Histology
[I+M] vs. [D]	0.211	0.506	0.272-0.941	0.032*

Multivariate survival analysis demonstrated that weak or negative expression of CDH17, advanced stage, more lymph node metastases, and diffuse-type histology are independent factors for significantly worse prognosis. HR, Hazard ratio; CI, confidence interval. I, intestinal type; M, mixed type; D, diffuse type.

^*p <0.05,

^**p <0.01.